The U.S. Food and Drug Administration on Wednesday approved Mesoblast's cell therapy for treating a type of complication that occurs after a stem cell or bone marrow transplant called ...

Calquence is under clinical development by AstraZeneca and currently in Phase II for Graft Versus Host Disease (GVHD).

New imaging technique able to identify early signs of graft-versus-host-disease in transplant patients. Read on!

TRX-103 is under development for the treatment of graft versus host disease (GvHD), Crohn’s disease and unspecified indication. The therapeutic candidate comprises of allogenic Treg-cells which are ...

Graft-versus-host disease (GvHD) is a complication of a bone marrow or stem cell transplant in which cells from a donor attack the tissues of the recipient. GvHD can be classified as being either ...

Let’s cover six scientifically backed methods to address the post-stem cell transplant procedure side effects you may be experiencing.

The FDA approved several drugs in December for the treatment of diseases including pancreatic adenocarcinoma, lung cancer, ...

The researchers found that itacitinib resulted in low CRS grades; 22%, 78%, and 0% of patients had grades 0, 1, and 2 to 5, respectively. (HealthDay News) — For patients with haploidentical ...

The allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy Ryoncil (remestemcel-L-rknd) has been approv ...

Mesoblast's FDA approval for remestemcel marks a milestone for MSC therapies, but limited cash reserves pose risks for US ...

INR:6468. gta san 1 century-old miracle drug & 2 billion-dollar products & 4 blockbuster drugs: the future of antithrombotic drugs is still promising Strategies for the d ...